Dr. George Logothetis

Dr. Erin D. Michos is a Professor of Medicine within the Division of Cardiology at Johns Hopkins School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women's Cardiovascular Health and the Associate Director of Preventive Cardiology within the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Dr. Michos is an internationally known expert in Preventive Cardiology and Women’s Health, having authored >700 publications and 11 book chapters. Her research involves (1) Women’s Cardiovascular Health; (2) Lipids and Lipid management; (3) Cardio-Kidney-Metabolic and Obesity disease management (4) Coronary artery calcium, inflammation and biomarkers of cardiovascular risk. She is the co-Editor-in-Chief for the American Journal of Preventive Cardiology. She is Co-Director of the IMPACT Center (Improving Participation Among Diverse Populations in Cardiovascular Clinical Trials) at Johns Hopkins, funded by the American Heart Association (AHA). She is a co-investigator in several NIH-funded studies including the Multi-Ethnic Study of Atherosclerosis and Atherosclerosis Risk in Communities cohorts. She has served as the Training Director for four AHA Strategic Focused Research Networks. She has mentored over 60 individuals and the recipient of 2 mentoring awards. Additionally, she was the recipient of the Nanette Wegner Award for Women’s Health Medical Leadership by the Women Heart Organization and the Donna Vogel Women’s Health Champion Award by Johns Hopkins University. Dr. Michos completed medical school at Northwestern University, Internal Medicine residency and Cardiology fellowship at the Johns Hopkins Hospital, and a Masters of Health Science degree at the Johns Hopkins Bloomberg School of Public Health. Dr. Michos is highly rated in 30 conditions, according to our data. Her top areas of expertise are Atherosclerosis, Vitamin D Deficiency, Heart Failure, Percutaneous Coronary Intervention (PCI), and Thrombectomy.

Dr. Michael J. Blaha MD MPH is Professor of Cardiology and Epidemiology and presently serves as the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Director of the Cardiometabolic Clinic, and Program Director for the Preventive Cardiology Fellowship. His clinical interests include primary and secondary prevention of cardiovascular disease, with emphasis on early intervention in patients with advanced subclinical atherosclerosis detected with cardiac computed tomography. Dr. Blaha represents the 4th generation of physicians in his family. After earning a BS in pre-medical studies and classical civilization at the University of Notre Dame in 2001, Dr. Blaha went to Vanderbilt University where in 2006 he received his MD as well as an MPH. in clinical epidemiology and biostatistics. Dr. Blaha then completed his Internal Medicine residency in the Osler Medical Housestaff Training Program at Johns Hopkins in 2009 before completing a fellowship in Cardiology at Johns Hopkins in 2012. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 30 trainees, many of which have gone on to hold prominent academic appointments. In 2021, Dr. Blaha was named to the Clarivate Highly Cited Researcher List, representing the top 1% of world’s researchers, and was first named to the Baltimore Magazine Best Doctors List. In 2022, he received the Arthur S. Agatston Cardiovascular Disease Prevention Award. Clinically, he practices as a preventive cardiologist specializing in cardiometabolic disease and in the interpretation of cardiac CT. His clinic specializes in patients with cardiometabolic disease and advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk. Dr. Blaha is highly rated in 24 conditions, according to our data. His top areas of expertise are Atherosclerosis, Coronary Heart Disease, High Cholesterol, Metabolic Syndrome, and Percutaneous Coronary Intervention (PCI).

Roger Blumenthal is the Kenneth Jay Pollin Professor of Cardiology, professor of medicine and director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease in Baltimore, Maryland. His principal clinical and research interests involve: 1) strategies to improve cardiovascular risk assessment to identify those adults at elevated risk and those at very low risk of cardiovascular disease and 2) the optimal management of atherosclerotic vascular disease. He is an expert in the pathogenesis, treatment and prevention of atherosclerotic vascular disease. Dr. Blumenthal was the principal developer of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. He is on the official national spokesperson panel for the American Heart Association and has co-written more than 600 articles dealing with many aspects of coronary heart disease and atherosclerosis management. An experienced writer, Dr. Blumenthal is on the editorial board of Circulation, Cardiology Today, and The American College of Cardiology and Extended Learning Center. He is a fellow of the American College of Cardiology and the American Heart Association’s Epidemiology and Prevention Council. He was co-editor-in-chief of the textbook Preventive Cardiology – A Companion to Braunwald’s Heart Disease. He received his medical degree from Cornell Medical College, where he was awarded the Weiss Prize for Excellence in Clinical Medicine. He did his internal medicine and cardiology fellowship training at The Johns Hopkins Hospital before joining the Johns Hopkins cardiology faculty. Dr. Blumenthal was the 2019 recipient of the Landon School Anthony Kupka Distinguished Alumnus Award. He was co-chairperson of the 2019 American College of Cardiology/American Heart Guideline on prevention of cardiovascular disease. Dr. Blumenthal is highly rated in 19 conditions, according to our data. His top areas of expertise are Atherosclerosis, Coronary Heart Disease, Metabolic Syndrome, Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery.